iSelect Fund — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Holobiome discovers and develops therapies derived from the human gut microbiome, working to translate microbiome science into probiotics and targeted treatments for whole-body health.
AI & Machine LearningBiotechHealthtechLongevityBoston, US
Philip Strandwitz(Co-founder & Director, Chief Executive Officer)inKim Lewis(Co-founder, Director)Mike La Fleur(President, Co-founder, Director)Michael LaFleur(Executive Officer)
BoardJoan LaRovere(Director)inIain Chessell(Director)
Co-investorsAble PartnersBantam GroupHealthtech CapitalPace VenturesAlexandriaDeep Future+3 more
Pairidex offers FusionMRD, a personalized digital droplet PCR (ddPCR) assay that detects and quantifies oncogenic gene fusions from a standard peripheral blood sample to monitor treatment response and minimal residual disease in gene fusion-driven blood cancers such as leukemia.
BiotechDigital HealthHealthtechMedical DevicesSt. Louis, US
Grant Challen(Co-Founder & Scientific Advisor)inAllyson Mayer(Interim COO)inAndrew Young(Founder & CSO)Paul Kortschak(CEO)in
BoardTodd Druley(Director)Crystal Winkeler(Director)
Co-investorsBioGenerator Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.